|Bid||0.00 x 1100|
|Ask||39.98 x 1100|
|Day's Range||38.28 - 39.06|
|52 Week Range||26.54 - 39.17|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Varian Medical (VAR) opts to spread radiotherapy accessibility in Latin America through Brazil MOH, other international ventures of the company hold promise.
A rapidly changing healthcare environment in the United States, sluggish first quarter, declining margins and foreign exchange headwinds continue to hurt DENTSPLY SIRONA (XRAY).
Anika Therapeutics (ANIK) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Successive product launches and a marked progress in precision medicine initiatives boost Thermo Fisher's (TMO) performance.
Post takeover of Abaxis' (ABAX) point-of-care diagnostic instruments, Zoetis expects the consolidated company's veterinary diagnostics category to speed up growth over the animal health industry.
Veeva Systems' (VEEV) new commercial data warehouse establishes a solid data foundation, which will boost AI and analytics in the MedTech industry.
A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).
Within Genomic Health's (GHDX) prostate cancer business, strengthened NCCN prostate cancer guidelines and additional new data increase private coverage for the Oncotype DX GPS test.
On a per-share basis, the Redwood City, California-based company said it had a loss of 11 cents. Earnings, adjusted for non-recurring costs, came to 13 cents per share. The results topped Wall Street expectations. ...
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How far off is Genomic Health Inc (NASDAQ:GHDX) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock isRead More...
The Redwood City, California-based company said it had profit of 5 cents per share. Earnings, adjusted for non-recurring costs, were 8 cents per share. The results fell short of Wall Street expectations. ...
Genomic Health Inc’s (NASDAQ:GHDX): Genomic Health, Inc. provides actionable genomic information to personalize cancer treatment decisions worldwide. The US$1.12B market-cap posted a loss in its most recent financial year ofRead More...
There were some huge moves in the biotech space in the past week, with Portola Pharmaceuticals Inc (NASDAQ: PTLA ) slumping over 25 percent on perceived FDA risk after the company said the FDA may mandate ...